Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | USP19 | O94966 | 9/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 2/20 | 0.32 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4286413 | 0.93 | USP19 (0.39) | ADRA2AUSP19CCR5OPRM1OPRL1 | |
| SCHEMBL4291374 | 0.91 | USP19 (0.36) | USP19LMNATSHRSMN1; SMN2HCRTR1 | |
| SCHEMBL4287236 | 0.91 | ADRA2A (0.39) | ADRA2AUSP19LMNANPSR1TSHR | |
| SCHEMBL4284651 | 0.90 | USP19 (0.35) | USP19NPSR1EGLN3KDM4EALDH1A1 | |
| SCHEMBL4293642 | 0.89 | USP19 (0.37) | USP19HCRTR1HCRTR2 | |
| SCHEMBL4291024 | 0.89 | USP19 (0.39) | USP19HCRTR1HCRTR2 | |
| SCHEMBL4286715 | 0.88 | USP19 (0.36) | USP19 | |
| SCHEMBL13705363 | 0.88 | USP19 (0.36) | USP19 | |
| SCHEMBL4287445 | 0.88 | USP19 (0.35) | USP19TSHRHCRTR1HCRTR2 | |
| SCHEMBL13705362 | 0.88 | USP19 (0.36) | USP19HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | ADRA2A 1573/4885USP19 1993/4885LMNA 1785/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | ADRA2A 1573/4885USP19 1993/4885LMNA 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.